Now reimag­in­ing home, of­fice sched­ules: No­var­tis CEO Vas Narasimhan sees a new nor­mal in the post-Covid era

5 years ago
Bioregnum

Pa­tient deaths force Astel­las to write off $540M of their $3B gene ther­a­py buy­out as time­line grows and tar­get group ...

5 years ago
Pharma

Bio­gen's Michel Vounatsos takes home $18.7M in pay as the com­pa­ny bat­tles to take ad­u­canum­ab to mar­ket

5 years ago
People
Pharma

Eli Lil­ly aban­dons its plans to pitch its block­buster con­tender mirik­izum­ab for pso­ri­a­sis af­ter siz­ing up heavy­weight ...

5 years ago
R&D

Bio­gen re­vers­es course on com­pas­sion­ate use for ALS drug tofersen with plans to open pro­gram in Ju­ly

5 years ago
Pharma
Cell/Gene Tx

Es­pe­ri­on's strug­gling-to-mar­ket, would-be block­buster finds fresh in­fu­sion of cash

5 years ago
Deals

Arch On­col­o­gy thinks it can stand out in the red-hot CD47 field, and it's tak­ing $105M in new cash to prove it

5 years ago
Financing

Af­ter fac­ing a 16-month so­journ dur­ing Covid to over­come a stun­ning CRL, lit­tle En­zy­vant says it's back on track — ...

5 years ago
Startups
FDA+

For tai­lored, sin­gle-per­son an­ti­sense oligonu­cleotides, FDA of­fers guid­ance on non­clin­i­cal test­ing

5 years ago
Cell/Gene Tx
FDA+

X-Bi­otix sus­pends R&D ef­forts amid dearth of fi­nanc­ing for an­tibi­otics re­search; Ver­tex picks a pain drug for ...

5 years ago
News Briefing

The Car­lyle Group shells out $435M for con­trol­ling stake in vac­cine, gene ther­a­py ser­vices com­pa­ny

5 years ago
Deals

Loxo founder Josh Bilenker, No­var­tis on­col­o­gy leader Jeff En­gel­man join forces to de­but can­cer R&D play­er

5 years ago
Startups
R&D

Re­gen­eron's Len Schleifer, George Yan­copou­los start their am­bi­tious 5-year plan, earn­ing a front-loaded $270M ...

5 years ago
People
Pharma

Biden signs two bills to clar­i­fy new chem­i­cal en­ti­ties, ed­u­cate on biosim­i­lars

5 years ago
Pharma
FDA+

Ex­clu­sive: Ul­ti­mate biotech in­sid­er Dan Lynch takes his 30 years of ex­pe­ri­ence to GV to fill a new­ly-cre­at­ed post

5 years ago
People

UniQure gets an­oth­er shot with he­mo­phil­ia gene ther­a­py af­ter FDA lifts clin­i­cal hold; Ne­oleuk­in's IL-2 hope­ful al­so ...

5 years ago
Cell/Gene Tx
FDA+

Covid-19 roundup: Eu­ro­pean Com­mis­sion sues As­traZeneca over vac­cine sup­plies; South Africa re­sumes J&J vac­cine tri­al

5 years ago
Coronavirus

FDA gives Ax­some speedy re­view for de­pres­sion drug, while oth­er in­di­ca­tions wait in the wings

5 years ago
FDA+

Sanofi lands 3rd Covid-19 vac­cine man­u­fac­tur­ing part­ner as it works to push for­ward its own jab

5 years ago
Coronavirus
Manufacturing

As­traZeneca and Sanofi tout break­through in €645M al­liance against lead­ing cause of in­fant death

5 years ago
R&D

Christoph West­phal and the crew at No­var­tis-backed TScan aren't wait­ing to take their pre­clin­i­cal TCR pitch to Nas­daq

5 years ago
Financing

Lat­est news: Com­mit­tee votes to restart J&J vac­ci­na­tions, check­point gi­ants prep de­fense, un­der­dog vac­cine en­ters the ...

5 years ago
Weekly

J&J vac­ci­na­tions re­sume as FDA, CDC con­fi­dent in ben­e­fit-risk pro­file

5 years ago
FDA+
Coronavirus

ADC Ther­a­peu­tics nabs its first ap­proval as FDA of­fers a quick OK for its DL­B­CL can­cer treat­ment

5 years ago
FDA+
First page Previous page 702703704705706707708 Next page Last page
A service from the Financial Times